Theravance Biopharma (TBPH) Net Cash Flow (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Net Cash Flow of $120.3 million for Q1 2026, up 65.2% year-over-year from $72.8 million in Q1 2025, and up 1826.64% quarter-over-quarter from -$7.0 million in Q4 2025.
Theravance Biopharma (TBPH) Net Cash Flow (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Net Cash Flow for 13 consecutive years, with $120.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 65.2% year-over-year to $120.3 million; the TTM figure through Mar 2026 stood at $177.5 million (up 212.59% YoY), while the FY2025 annual figure was $130.0 million, up 7537.59% from the prior year.
- Net Cash Flow improved to $120.3 million in Q1 2026 per TBPH's latest filing, from -$7.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $171.3 million in Q2 2025 and bottomed at -$758.3 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$40.7 million across 5 years, with a median of -$7.1 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow sank 2607.53% — and 2025, when it jumped 2387.22%.
- Theravance Biopharma's Net Cash Flow stood at $78.8 million in 2022, then slumped by 140.79% to -$32.1 million in 2023, then jumped by 144.86% to $14.4 million in 2024, then tumbled by 148.32% to -$7.0 million in 2025, then surged by 1826.64% to $120.3 million in 2026.
- Business Quant data shows TBPH's Net Cash Flow at $120.3 million in Q1 2026, -$7.0 million in Q4 2025, and -$107.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -68.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.34 Mn |
| Jun 30, 2026 | -68.34 Mn |
| Mar 31, 2026 | 120.30 Mn |
| Mar 31, 2026 | 120.30 Mn |
| Dec 31, 2025 | -6.97 Mn |
| Dec 31, 2025 | -6.97 Mn |
| Sep 30, 2025 | -107.15 Mn |
| Sep 30, 2025 | -107.15 Mn |
| Jun 30, 2025 | 171.31 Mn |
| Jun 30, 2025 | 171.31 Mn |
| Mar 31, 2025 | 72.82 Mn |
| Mar 31, 2025 | 72.82 Mn |
| Dec 31, 2024 | 14.42 Mn |
| Dec 31, 2024 | 14.42 Mn |
| Sep 30, 2024 | -22.97 Mn |
| Sep 30, 2024 | -22.97 Mn |
| Jun 30, 2024 | -7.49 Mn |
| Jun 30, 2024 | -7.49 Mn |
| Mar 31, 2024 | 14.29 Mn |
| Mar 31, 2024 | 14.29 Mn |